One possible explanation is that BOADICEA v5 uses the population breast cancer incidences of the United Kingdom as baseline risk, which are slightly lower than those in the Netherlands.1 But more importantly, data on family history, mammographic density, and rare high-risk variants in BRCA1 and BRCA2 were lacking in our cohort. This evidence concerns the gene BRCA2 and breast carcinoma.